Reporting sexual function disorders caused by antipsychotic drugs: is there a role for the community pharmacy?
- 43 Downloads
Sexual function disorders are frequent adverse effects of antipsychotic use. These effects can lead to non‐compliance to medication, which dramatically worsen the outcome of the psychotic disease. Detecting sexual dysfunction by the carers may be difficult, since feelings of embarrassment may occur in both care‐taker as in patient. In order to prevent underreporting, strategies to recognise sexual dysfunction should be developed, based upon collaboration between care providers of the psychotic patient. Community pharmacies in many countries can detect non‐compliance to medication in prescription data and report this to psychiatric services of the patient. Exchanging information by cross‐sectoral networks may optimise the disease management of the psychotic patient.
Unable to display preview. Download preview PDF.
- 1.Arnt J. Pharmacological differentiation of classical and novel antipsychotics. Int Clin Psychopharm 1998;13:S7-S14.Google Scholar
- 2.Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999;35:S61-6.Google Scholar
- 3.Coffey M. Psychosis and medication: strategies for improving adherence. Br J Nurs 1999;8:225-30.Google Scholar
- 4.Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35:S75-86.Google Scholar
- 5.Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-7.Google Scholar
- 6.Ghitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psych 1994;55:406-13.Google Scholar
- 7.Kinon BJ, Lieberman JA. Mechanisms of actions of atypical antipsychotic drugs: a critical analysis. Psychopharm 1996;124:2-34.Google Scholar
- 8.Knegtering H, Lambers PA, Prakken G, Ten Brink C. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review. Acta Neuropsychiatrica 2000;12:19-26.Google Scholar
- 9.Knegtering H, Boks M, Blijd C, Wiersma D, Van den Bosch RJ. Sexual dysfunctions in patients using risperidone or olanzapine: a randomized trial. Submitted 2001Google Scholar
- 10.Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999; 35: S67-73.Google Scholar
- 11.Perkins DO. Adherence to antipsychotic mediciations. J Clin Psychiatry 1999;60: S25-S30.Google Scholar
- 12.Santoni JP, Saubuda S. Adverse events associated with neuroleptic drugs: focus on neuroendocriene reactions. Acta Ther 1995;21:193-304.Google Scholar
- 13.Sitland-Marken PA, Well G, Froemming JH, Chu CC, Brown CS Psychiatric application of bromocriptine therapy. J Clin Psychiatry 1990;51: 68-82.Google Scholar
- 14.Salerian AJ, Deibler WE, Vittone BJ, Geyer SP, Drell L, Mirmirani N et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther 2000; 26:133-40Google Scholar
- 15.Solovitz BL, Fisher S, Bryant SG et al. How well can patients discriminate drug-related side effects from extraneous new symptoms? Psychopharmacol Bull 1987;23: 189-192.Google Scholar